vaccine Pancreatic cancer It could serve as a promising new treatment.
At Memorial Sloan Keter Keene Center (MSK) in New York, an experimental approach to treat cancer with messenger RNA (mRNA)-based therapeutic vaccines is “potential” in reducing the risk of reversing the disease after surgery. It continues to show. press release.
Results from Phase 1 clinical trialpublished in Nature, revealed that the vaccine triggered an immune response in a small group of patients.
Cancer vaccines show promising results for certain patients
The activation of this immune cell was lasting nearly four years after treatment, the release said.
Patients received vaccine Additionally, immune system responses were likely to remain cancer-free after 3 years of follow-up.
The results of phase 1 clinical trials “continue to show potential,” MSK reported in a press release. (istock)
Dr. Vinod Balachandran, the lead investigator of the MSK trial and senior study author, expressed optimism about the effectiveness of this treatment.
“We found that using RNA vaccine technology can be recognized by the immune system. Pancreatic cancerand this immune response could potentially last for many years,” he said.
“The ability to trigger a robust, long-term immune response is a necessary feature of any cancer vaccine.”
This US prostate cancer case is skyrocketing as doctors probably share the reason
Pancreatic cancer is “difficult to treat,” so Balachandran shared his surprise that the immune system responded in some patients.
“We recommend that you make sure our approach can teach you Immune system “To recognize pancreatic cancer, the immune response is strong and can potentially affect patients,” he said.
“The ability to trigger a robust, long-term immune response is a necessary feature of any cancer vaccine.”
“The findings are promising, but these vaccines are still in the early stages of testing,” Balachandran said.
The team is planning a larger study “to further test cancer vaccines by these treatments in patients with surgically removable pancreatic cancer.”
Therapeutic vaccines can surgically remove tumors and target early stages of cancer that have not spread. (istock)
Of the 16 participants, the vaccine stimulated an immune response in half of them. Cancer vaccines were personalized to target specific proteins found in the form of disease by each participant.
Patients also received Immunotherapeutics (atezolizumab) and standard chemotherapy after surgery.
Click here to get the Fox News app
Researchers say that by training the immune system to “recognize cancer cells as foreign bodies,” such a therapeutic cancer vaccine, called autogensevimeran, treats cancer, rather than preventing cancer. It is intended to do so.
Patients who had an immune response to the vaccine were more likely to reduce their risk of cancer with three years of testing. (istock)
Vaccines aim to target early stages of non-spread cancer that can surgically remove tumors, and can “delay or prevent recurrence.”
Balachandran pointed out that this approach could also be applied to other forms of cancer.
“If we can do this with pancreatic cancer, we could theoretically develop a vaccine for treating other cancer types.”
“For patients with pancreatic cancer, our latest results continue to support an approach that uses individual mRNA vaccines to target new antigens in each patient’s tumor,” he said.
“If we can do this with pancreatic cancer, we could theoretically develop a vaccine for treating other cancer types.”
Visit us for more health articles www.foxnews.com/health
Pancreatic cancer remains one of the most fatal cancers, as only about 13% of patients live five years after diagnosis, according to MSK and the American Cancer Society.
Click here to sign up for our health newsletter
Common treatments Like chemotherapy, radiation and immunotherapy “have little effect on pancreatic cancer,” MSK said, adding that new treatments “urgently need.”
